1. Robak T, Błoń­ski J, Skot­nic­ki AB, Pio­trow­ska M, Wró­bel T, Ryb­ka J, Kłocz­ko J, Boł­kun Ł, Budzi­szew­ska BK, Wal­czak U, Uss A, Fidec­ka M, Smo­lew­ski P. Ritu­xi­mab, cla­dri­bi­ne, and cyc­lo­pho­spha­mi­de (RCC) induc­tion with ritu­xi­mab main­te­nan­ce in chro­nic lym­pho­cy­tic leu­ke­mia: PALG — CLL4 (ML21283) trial. Eur J Haema­tol. 2018 May;100(5):465–474.

Ack­now­led­ge­ments: The stu­dy was sup­por­ted by grant fun­ding from Roche Poland ML21283 trial, the Medi­cal Uni­ver­si­ty of Lodz, Poland: Grants: No. 503/1–152-01/503–11-002, 503/1–093-01/503–11-003 and 502–03/8–093-01/502–64-032.

2. Robak T, Blon­ski JZ, Waw­rzy­niak E, Gora-Tybor J, Palacz A, Dmo­szyn­ska A, Konop­ka L, Warzo­cha K, Jam­ro­ziak K. Acti­vi­ty of cla­dri­bi­ne com­bi­ned with cyc­lo­pho­spha­mi­de in fron­tli­ne the­ra­py for chro­nic lym­pho­cy­tic leu­ke­mia with 17p13.1/TP53 dele­tion: report from the Polish Adult Leu­ke­mia Gro­up. Can­cer. 2009 Jan 1;115(1):94–100.

Sup­por­ted in part by the grants from the Mini­stry of Scien­ce, War­saw Poland (2P05B01828) and the Medi­cal Uni­ver­si­ty of Lodz (503‑1093‑1) and by the Foun­da­tion for the Deve­lop­ment of Dia­gno­stics and The­ra­py, War­saw, Poland.

3. Robak T, Smo­lew­ski P, Cebu­la B, Grzy­bow­ska-Izy­dor­czyk O, Błoń­ski JZ. Ritu­xi­mab plus cla­dri­bi­ne with or witho­ut cyc­lo­pho­spha­mi­de in patients with relap­sed or refrac­to­ry chro­nic lym­pho­cy­tic leu­ke­mia. Eur J Haema­tol. 2007 Aug;79(2):107–13.  Ack­now­led­ge­ments

This stu­dy was sup­por­ted in part by grant from the Medi­cal Uni­ver­si­ty of Lodz (no. 503‑1093‑1) and by the Foun­da­tion for the Deve­lop­ment of Dia­gno­stics and The­ra­py, War­saw, Poland.

4. Robak T, Jam­ro­ziak K, Gora-Tybor J, Blon­ski JZ, Kasz­nic­ki M, Dwi­le­wicz-Tro­ja­czek J, Wia­ter E, Zdun­czyk A, Dybo­wicz J, Dmo­szyn­ska A, Woj­tasz­ko M, Zdziar­ska B, Cal­bec­ka M, Kosty­ra A, Hel­l­mann A, Lewan­dow­ski K, Stel­la-Holo­wiec­ka B, Sulek K, Gaw­ron­ski K, Skot­nic­ki AB, Nowak W, Zawil­ska K, Molen­do­wicz-Por­ta­la L, Klocz­ko J, Soko­low­ski J, Warzo­cha K, Sefe­ryn­ska I, Cegla­rek B, Konop­ka L. Cla­dri­bi­ne in a weekly ver­sus daily sche­du­le for untre­ated acti­ve hairy cell leu­ke­mia: final report from the Polish Adult Leu­ke­mia Gro­up (PALG) of a pro­spec­ti­ve, ran­do­mi­zed, mul­ti­cen­ter trial. Blo­od. 2007 May 1;109(9):3672–5.

This work was sup­por­ted by a grant from the Mini­stry of Scien­ce (no. 2P05B01828).

5. Wierz­bow­ska A, Robak T, Plu­ta A, Waw­rzy­niak E, Cebu­la B, Hoło­wiec­ki J, Kyrcz-Krze­mień S, Gro­sic­ki S, Gie­bel S, Skot­nic­ki AB, Piat­kow­ska-Jaku­bas B, Kulicz­kow­ski K, Kieł­biń­ski M, Zawil­ska K, Kłocz­ko J, Wrze­sień-Kuś A; Polish Adult Leu­ke­mia Gro­up. Cla­dri­bi­ne com­bi­ned with high doses of ara­bi­no­si­de cyto­si­ne, mito­xan­tro­ne, and G‑CSF (CLAG‑M) is a high­ly effec­ti­ve salva­ge regi­men in patients with refrac­to­ry and relap­sed acu­te myelo­id leu­ke­mia of the poor risk: a final report of the Polish Adult Leu­ke­mia Gro­up. Eur J Haema­tol. 2008 Feb;80(2):115–26.

This work was in part sup­por­ted by the grant of Medi­cal Uni­ver­si­ty of Lodz No. 503‑1093‑1.

6. Robak T, Smo­lew­ski P, Urban­ska-Rys H, Gora-Tybor J, Blon­ski JZ, Kasz­nic­ki M. Ritu­xi­mab fol­lo­wed by cla­dri­bi­ne in the tre­at­ment of heavi­ly pre­tre­ated patients with indo­lent lym­pho­id mali­gnan­cies. Leuk Lym­pho­ma. 2004 May;45(5):937–44.

The stu­dy was sup­por­ted in part by the grant from the Medi­cal Uni­ver­si­ty of Lodz (No 503–106‑2) and by the Foun­da­tion for the Deve­lop­ment of Dia­gno­stics and The­ra­py, War­saw, Poland.

7. Robak T, Błoń­ski JZ, Kasz­nic­ki M, Góra-Tybor I, Dwi­le­wicz-Tro­ja­czek J, Bogu­radz­ki P, Konop­ka L, Cegla­rek B, Sułek J, Kulicz­kow­ski K, Woło­wiec D, Stel­la-Hoło­wiec­ka B, Skot­nic­ki AB, Nowak W, Moskwa-Sro­ka B, Dmo­szyń­ska A, Cal­bec­ka M. Cla­dri­bi­ne com­bi­ned with cyc­lo­pho­spha­mi­de and mito­xan­tro­ne as front-line the­ra­py in chro­nic lym­pho­cy­tic leu­ke­mia. Leu­ke­mia. 2001 Oct;15(10):1510–6.

This work was sup­por­ted in part by grant No. 4P05B06019, from KBN, War­saw, Poland.

8. Robak T, Góra-Tybor J, Lech-Marań­da E, Błoń­ski JZ, Kasz­nic­ki M. Cla­dri­bi­ne in com­bi­na­tion with mito­xan­tro­ne and cyc­lo­pho­spha­mi­de (CMC) in the tre­at­ment of heavi­ly pre-tre­ated patients with advan­ced indo­lent lym­pho­id mali­gnan­cies. Eur J Haema­tol. 2001 Mar;66(3):188–94.

Ack­now­led­ge­ments: This work was sup­por­ted in part by Grants nos. 4PO 5B06019 from KBN, War­saw, and 503±107±2 from the Medi­cal Uni­ver­si­ty of Lodz, Poland.